Q2 2024 EPS Estimates for Repligen Co. Reduced by Analyst (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGEN) – Research analysts at William Blair reduced their Q2 2024 earnings per share estimates for Repligen in a report released on Thursday, May 2nd. William Blair analyst M. Larew now anticipates that the biotechnology company will post earnings of $0.29 per share for the quarter, down from their prior forecast of $0.32. The consensus estimate for Repligen’s current full-year earnings is $1.46 per share. William Blair also issued estimates for Repligen’s Q1 2025 earnings at $0.49 EPS, Q2 2025 earnings at $0.53 EPS, Q3 2025 earnings at $0.59 EPS and Q4 2025 earnings at $0.62 EPS.

Other equities analysts also recently issued research reports about the stock. JPMorgan Chase & Co. dropped their price target on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday. Stifel Nicolaus boosted their target price on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Finally, KeyCorp increased their price target on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus price target of $197.75.

Repligen Price Performance

Shares of RGEN opened at $167.05 on Friday. The company has a market cap of $9.33 billion, a P/E ratio of 668.23, a PEG ratio of 5.44 and a beta of 1.03. Repligen has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The company has a quick ratio of 5.75, a current ratio of 6.35 and a debt-to-equity ratio of 0.26. The firm’s 50 day moving average price is $180.81 and its 200 day moving average price is $174.09.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.01). The firm had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The company’s quarterly revenue was down 17.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.64 earnings per share.

Hedge Funds Weigh In On Repligen

A number of hedge funds and other institutional investors have recently made changes to their positions in RGEN. BI Asset Management Fondsmaeglerselskab A S lifted its position in Repligen by 173.3% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 2,848 shares of the biotechnology company’s stock worth $524,000 after acquiring an additional 1,806 shares during the period. Central Pacific Bank Trust Division acquired a new stake in shares of Repligen during the first quarter worth $502,000. Daiwa Securities Group Inc. grew its position in Repligen by 243.0% in the 1st quarter. Daiwa Securities Group Inc. now owns 11,319 shares of the biotechnology company’s stock valued at $2,082,000 after buying an additional 8,019 shares during the last quarter. Hardy Reed LLC acquired a new position in Repligen in the 1st quarter valued at $232,000. Finally, Fidelis Capital Partners LLC purchased a new position in Repligen during the 1st quarter worth $115,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling at Repligen

In other news, COO James Bylund sold 4,373 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the sale, the chief operating officer now owns 14,135 shares in the company, valued at approximately $2,799,860.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO James Bylund sold 4,373 shares of Repligen stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the sale, the chief operating officer now owns 14,135 shares in the company, valued at $2,799,860.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Karen A. Dawes sold 1,000 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the sale, the director now directly owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The disclosure for this sale can be found here. Insiders have sold 25,597 shares of company stock worth $5,039,532 over the last three months. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.